Pfizer Inc. $PFE Position Cut by GFS Advisors LLC

GFS Advisors LLC decreased its stake in Pfizer Inc. (NYSE:PFE) by 1.0% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 475,277 shares of the biopharmaceutical company’s stock after selling 4,805 shares during the quarter. Pfizer accounts for about 1.6% of GFS Advisors LLC’s investment portfolio, making the stock its 21st largest holding. GFS Advisors LLC’s holdings in Pfizer were worth $11,521,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of Pfizer by 0.9% during the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock valued at $13,257,004,000 after acquiring an additional 4,629,976 shares during the period. Northern Trust Corp raised its holdings in Pfizer by 6.8% in the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company’s stock valued at $1,579,340,000 after acquiring an additional 3,943,397 shares in the last quarter. Amundi increased its stake in shares of Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after purchasing an additional 15,758,846 shares during the last quarter. Invesco Ltd. grew its position in shares of Pfizer by 2.8% in the 1st quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company’s stock valued at $767,709,000 after buying an additional 838,198 shares during the last quarter. Finally, Deutsche Bank AG lifted its stake in shares of Pfizer by 7.0% in the 1st quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company’s stock valued at $715,581,000 after purchasing an additional 1,846,436 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of PFE opened at $24.81 on Friday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.82. The stock has a market cap of $141.03 billion, a P/E ratio of 13.19, a P/E/G ratio of 0.81 and a beta of 0.55. The business’s 50 day moving average price is $24.86 and its 200-day moving average price is $24.13. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the firm posted $0.60 EPS. Pfizer’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s dividend payout ratio is 91.49%.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday. UBS Group reissued a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Finally, Morgan Stanley lowered their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Pfizer currently has an average rating of “Hold” and an average target price of $28.35.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.